Literature DB >> 30680480

Clinical and molecular studies in two new cases of ARSACS.

Ivana Ricca1, Federica Morani1, Giacomo Maria Bacci2, Claudia Nesti1, Roberto Caputo2, Alessandra Tessa1, Filippo Maria Santorelli3.   

Abstract

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early-onset neurodevelopmental disorder characterized by the association of spastic ataxia and sensorimotor neuropathy. Additional features include retinal changes and cognitive impairment. Today, next-generation sequencing (NGS) techniques are allowing the rapid identification of a growing number of missense variants, even in less typical forms of the disease, but the pathogenic significance of these changes is often difficult to establish on the basis of classic bioinformatics criteria and genotype/phenotype correlations. Herein, we describe two novel cases of missense mutations in SACS. The two individuals were identified during the genetic screening of a large cohort of patients with inherited ataxias. We discuss how protein studies and specialized ophthalmological investigations could represent useful pointers for the interpretation of genetic data. Combination of these tools with NGS for rapid genotyping might help to identify new true ARSACS cases.

Entities:  

Keywords:  ARSACS; Genotype-phenotype correlation; Mitochondrial network; Retinal myelinated fibers; Sacsin

Mesh:

Year:  2019        PMID: 30680480     DOI: 10.1007/s10048-019-00564-7

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  20 in total

1.  Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS).

Authors:  Martine Girard; Roxanne Larivière; David A Parfitt; Emily C Deane; Rebecca Gaudet; Nadya Nossova; Francois Blondeau; George Prenosil; Esmeralda G M Vermeulen; Michael R Duchen; Andrea Richter; Eric A Shoubridge; Kalle Gehring; R Anne McKinney; Bernard Brais; J Paul Chapple; Peter S McPherson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  Mutations in SACS cause atypical and late-onset forms of ARSACS.

Authors:  J Baets; T Deconinck; K Smets; D Goossens; P Van den Bergh; K Dahan; E Schmedding; P Santens; V Milic Rasic; P Van Damme; W Robberecht; L De Meirleir; B Michielsens; J Del-Favero; A Jordanova; P De Jonghe
Journal:  Neurology       Date:  2010-09-28       Impact factor: 9.910

Review 3.  Clinical application of next generation sequencing in hereditary spinocerebellar ataxia: increasing the diagnostic yield and broadening the ataxia-spasticity spectrum. A retrospective analysis.

Authors:  Daniele Galatolo; Alessandra Tessa; Alessandro Filla; Filippo M Santorelli
Journal:  Neurogenetics       Date:  2017-12-06       Impact factor: 2.660

4.  Optical coherence tomography in autosomal recessive spastic ataxia of Charlevoix-Saguenay.

Authors:  Michael H Parkinson; Ana P Bartmann; Lisa M S Clayton; Suran Nethisinghe; Rolph Pfundt; J Paul Chapple; Mary M Reilly; Hadi Manji; Nicholas J Wood; Fion Bremner; Paola Giunti
Journal:  Brain       Date:  2018-04-01       Impact factor: 13.501

5.  Myelinated retinal fibers in autosomal recessive spastic ataxia of Charlevoix-Saguenay.

Authors:  E M Vingolo; R Di Fabio; S Salvatore; G Grieco; E Bertini; V Leuzzi; C Nesti; A Filla; A Tessa; F Pierelli; F M Santorelli; C Casali
Journal:  Eur J Neurol       Date:  2011-01-25       Impact factor: 6.089

6.  Autosomal recessive spastic ataxia of Charlevoix-Saguenay.

Authors:  Yoshihisa Takiyama
Journal:  Neuropathology       Date:  2006-08       Impact factor: 1.906

7.  Identification of mutations in AP4S1/SPG52 through next generation sequencing in three families.

Authors:  A Tessa; R Battini; A Rubegni; E Storti; C Marini; D Galatolo; R Pasquariello; F M Santorelli
Journal:  Eur J Neurol       Date:  2016-07-22       Impact factor: 6.089

8.  Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission.

Authors:  Ruben K Dagda; Salvatore J Cherra; Scott M Kulich; Anurag Tandon; David Park; Charleen T Chu
Journal:  J Biol Chem       Date:  2009-03-10       Impact factor: 5.157

9.  Retinal nerve fibre layer thickness in ARSACS: myelination or hypertrophy?

Authors:  Elena Garcia-Martin; Luis E Pablo; Jose Gazulla; Vicente Polo; Antonio Ferreras; Jose M Larrosa
Journal:  Br J Ophthalmol       Date:  2012-10-17       Impact factor: 4.638

10.  Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum.

Authors:  Matthis Synofzik; Anne S Soehn; Janina Gburek-Augustat; Julia Schicks; Kathrin N Karle; Rebecca Schüle; Tobias B Haack; Martin Schöning; Saskia Biskup; Sabine Rudnik-Schöneborn; Jan Senderek; Karl-Titus Hoffmann; Patrick MacLeod; Johannes Schwarz; Benjamin Bender; Stefan Krüger; Friedmar Kreuz; Peter Bauer; Ludger Schöls
Journal:  Orphanet J Rare Dis       Date:  2013-03-15       Impact factor: 4.123

View more
  6 in total

1.  Functional Network Profiles in ARSACS Disclosed by Aptamer-Based Proteomic Technology.

Authors:  Federica Morani; Stefano Doccini; Giovanna Chiorino; Fabiana Fattori; Daniele Galatolo; Elisa Sciarrillo; Federica Gemignani; Stephan Züchner; Enrico Silvio Bertini; Filippo Maria Santorelli
Journal:  Front Neurol       Date:  2021-01-27       Impact factor: 4.003

Review 2.  Genetics of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and Role of Sacsin in Neurodegeneration.

Authors:  Jaya Bagaria; Eva Bagyinszky; Seong Soo A An
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

3.  Assessment of Sacsin Turnover in Patients With ARSACS: Implications for Molecular Diagnosis and Pathogenesis.

Authors:  Fabiana Longo; Daniele De Ritis; Annarita Miluzio; Davide Fraticelli; Jonathan Baets; Marina Scarlato; Filippo M Santorelli; Stefano Biffo; Francesca Maltecca
Journal:  Neurology       Date:  2021-10-14       Impact factor: 9.910

Review 4.  Documenting manifestations and impacts of autosomal recessive spastic ataxia of Charlevoix-Saguenay to develop patient-reported outcome.

Authors:  Marjolaine Tremblay; Laura Girard-Côté; Bernard Brais; Cynthia Gagnon
Journal:  Orphanet J Rare Dis       Date:  2022-10-01       Impact factor: 4.303

5.  Development of Nanostructured Lipid Carriers for the Delivery of Idebenone in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

Authors:  Chiara Martinelli; Matteo Battaglini; Carlotta Pucci; Sara Gioi; Chiara Caracci; Gaia Macaluso; Stefano Doccini; Filippo M Santorelli; Gianni Ciofani
Journal:  ACS Omega       Date:  2020-05-14

6.  Docosahexaenoic acid in ARSACS: observations in two patients.

Authors:  Ivana Ricca; Alessandra Tessa; Rosanna Trovato; Giacomo Maria Bacci; Filippo Maria Santorelli
Journal:  BMC Neurol       Date:  2020-05-28       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.